Prognostic value of oxygen inhalation therapy for simple nocturnal hypoxemia in COPD: a meta-analysis

doi:10.21203/rs.3.rs-3131083/v1

Download PDF

Research Article

Prognostic value of oxygen inhalation therapy for simple nocturnal hypoxemia in COPD: a meta-analysis

https://doi.org/10.21203/rs.3.rs-3131083/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted

You are reading this latest preprint version

Objective

The effect of oxygen therapy on the prognosis of chronic obstructive pulmonary disease (COPD) with nocturnal hypoxemia (NOD) has been controversial. Therefore, this study systematically evaluated the relevant literature and included it into randomized controlled studies for meta-analysis to evaluate the efficacy and prognosis.

Methods

We searched PubMed, EMBASE, web of science, Cochrane, China HowNet and Wanfang database for the literature on the prognosis of COPD patients with simple nod from the establishment of the database to June 30, 2022. The outcome indicators were death and aggravation of the disease. The efficacy evaluation measures were pulmonary function and arterial blood gas results. The publication bias and heterogeneity of the included studies were evaluated.

Results

A total of 621 patients from 5 studies were included in this meta-analysis, and there was no publication bias in the included studies. The total mortality of long-term oxygen therapy (LTOT) in COPD patients with simple nod in oxygen therapy group (RR = 1.04; 95% CI: 0.82–1.34, P = 0.73), mortality (RR = 0.85; 95% CI: 0.62–1.16, P = 0.31), risk of progression to LTOT events (RR = 1.07; 95% CI: 0.76–1.51, P = 0.68). PaO2 in patients with COPD and simple nod in oxygen therapy group was higher than that in non-oxygen therapy group (mean difference (MD) = 13.47; 95% CI: 3.49–23.46, P = 0.0008), the decrease of PaCO2 level was not statistically significant (MD = -10.05; 95% CI: -26.36-6.27, P = 0.23).

Conclusion

Oxygen therapy can improve the prognosis of blood oxygen partial pressure in COPD patients with simple nod, but oxygen therapy has no significant effect on the survival rate, controlling the progression of the disease to LTOT and reducing the partial pressure of carbon dioxide.

oxygen therapy

COPD

NOD

Prognosis

Meta analysis

Chronic obstructive pulmonary disease (COPD) is a common heterogeneous disease that can be prevented and treated. It is characterized by persistent respiratory symptoms and airflow restriction. It is usually caused by airway and/or alveolar abnormalities caused by obvious exposure to toxic particles or gases. Complications can increase the disability rate and mortality of COPD [1]. Its incidence rate continues to rise, and it is estimated that more than 5.4 million people will die of COPD and related diseases every year by 2060 [2]. The course of COPD is long, the condition is progressive, and the treatment effect of late COPD is poor, which seriously affects the quality of life of patients. Oxygen therapy is an important means to treat COPD patients with chronic persistent hypoxia symptoms and improve their prognosis [3].

With the development of oxygen therapy research, non-invasive ventilation, nasal high flow oxygen inhalation and other oxygen therapy methods are applied in the treatment of COPD. Long term oxygen therapy can improve the survival rate of patients with COPD hypoxemia (PaO2 < 60mmHg); the subjects of these studies are mostly patients with daytime hypoxemia. However, for patients with COPD who do not meet the criteria of long-term oxygen therapy, especially for patients whose PaO2 is not significantly reduced during the day but whose arterial oxygen saturation is decreased at night, less attention has been paid. Fletcher et al. [4] showed that the mortality of COPD patients with PaO2 above 60mmHg during the day but with simple nocturnal hypoxia destruction (NOD) increased significantly, which may be related to pulmonary hypertension and arrhythmia caused by insufficient alveolar ventilation or poor pulmonary ventilation perfusion during sleep [5]. In addition, whether oxygen therapy can improve the long-term survival rate of COPD patients with simple NOD is inconsistent with other outcomes. Chaouat et al [6] found that there was no significant difference in pulmonary artery pressure after two years between nocturnal oxygen therapy and non-oxygen therapy, and nocturnal oxygen therapy did not delay the time when patients began to use long-term oxygen therapy (LTOT). Cranston et al. [7] found that home oxygen therapy could significantly improve the survival rate of patients with daytime hypoxemia, but did not improve the survival rate of COPD patients with simple NOD. Tan et al [8] showed that the oxygen concentration was adjusted to 3–5 L/min according to the degree of hypoxia in COPD patients at different periods of night. As a result, the PaO2 of patients was improved, and the effect of oxygen therapy was better than that of continuous low flow oxygen inhalation. Fletcher et al [9] pointed out that nocturnal oxygen therapy (NOT) can improve the pulmonary artery pressure of patients with simple NOD in COPD, but the sample size was very small in the study, which affected the reliability of the study results to a certain extent.

Therefore, whether COPD patients with simple NOD need oxygen therapy, what kind of oxygen therapy measures should be taken, LTOT or NOT, and whether the effect of oxygen therapy can improve the prognosis of this population has been controversial. Therefore, this study evaluated the comprehensive efficacy and clinical prognosis of oxygen therapy and its measures in patients with simple NOD of COPD by systematic evaluation of relevant literature and meta-analysis of randomized controlled studies.

The inclusion and exclusion criteria were in accordance with the Cochrane Handbook for Systematic Reviews manual [10].

2.1 Inclusion Criteria and Exclusion Criteria

The inclusion criteria for this study are as follows: 1) Clinical study of oxygen therapy in patients with COPD nocturnal hypoxemia; 2) The end point of the study should include at least one of the following items: death, aggravation and readmission; The evaluation indexes of curative effect were pulmonary function and arterial blood gas; 3) Type of paper: Randomized, controlled study on oxygen therapy of COPD nocturnal hypoxemia; 4) The criterion of hypoxemia was that SaO2 < 90% time (SIT 90%) ≥ 30% of total sleep time.

The exclusion criteria for this study are as follows: 1) animal experiment; 2) Overview, commentary, case report, letter type literature, etc; 3) Repeated published literature; 4) Literature where the statistical method is not clear or the original data cannot be obtained.

2.2 Search Strategy

This study was registered in PROSPERO (CRD 42022367613). We searched PubMed, Embase, Web of Science, Cochrane, CNKI, and Wanfang database from the beginning of the database to June 30, 2022. Use the keyword search strategy to find all the literatures about "the effect of oxygen therapy on nocturnal hypoxemia of chronic obstructive pulmonary disease" (to select only the randomized controlled trial treatment of nocturnal oxygen therapy for COPD patients with simple nocturnal hypoxemia (that is, those who do not meet the long-term oxygen inhalation conditions). The search words are "chronic obstructive pulmonary disease" or "COPD", "Hypoxemia", "Oxygen therapy" or "Oxygen inhalation" "Efficacy" or "Prognosis". The two authors (Ling Sun and Ya-Fei Chang) independently searched and screened the literature, and negotiated with the third author (Quan-Xin Xie) to solve problems encountered.

2.3 Document Quality Evaluation and Data Extraction

We conducted data extraction and quality assessment by using the preferred reporting item (PRISMA) method of systematic evaluation and meta-analysis [11, 12]. Two authors (Ling Sun and Ya-Fei Chang) independently extracted the following data from eligible studies: the name of the first author, the year of publication, the source of the study object, the sample size, the basic characteristics of the subjects, the oxygen therapy program, the follow-up time, evaluation indicators, the study endpoint and its RR, 95% CI, and confounding factors. If RR and 95% CI are not directly provided in the original literature, we will contact the original author to obtain the required information. Two evaluators independently evaluated the quality of the literature included in the study by using the Newcastle Ottawa Scale scoring scale. Any ambiguous problems will be solved through discussion by all authors.

2.4 Statistical Analysis

The quality of the included study was assessed by the Cochrane Collaboration’s tool for Risk of bias. All cause death, deterioration of disease, re-hospitalization events, pulmonary function and arterial blood gas analysis results were counted. We used the inverse variance method to calculate Ln RR and standard error from the value of the natural logarithm of each study RR. We used Review Manager 5.3 software (The Cochrane Collaboration, Oxford, United Kingdom) for data analysis. When I² ≥ 50%, it indicates that there is statistical heterogeneity in the study, and a random effect model is used; Otherwise, select the fixed effect model. P ༜ 0.05 was statistically significant.

3.1 Literature Search Results

According to the retrieval criteria established in this study, we retrieved 1574 articles in total. By reading the title and abstract, we preliminarily excluded 1561 articles. Eight studies were excluded again by reading the text of the article: the data of three studies could not be combined for analysis or lacked extractable data, four studies did not follow up the subjects, and one study did not have a control group for its design type. Finally, five studies were included [6, 9, 13–15]. The process and results of retrieving articles are shown in Fig. 1.

3.2. Characteristics of the Included Studies

The five studies included 621 participants, 312 in the oxygen therapy group and 309 in the control group. Two studies were from Asian populations, two from Europe and one from the United States. The follow-up time in different studies ranged from 2 to 4 years. The general characteristics and article quality evaluation of the included literature are shown in Table 1. In general, the quality of the included studies was good, a flow chart of the quality assessment of the studies is shown in Fig. 2.

Table 1

Patient demographics, baseline and study characteristics
Author	Year	N	Design	Type of disease	Country	outcome/evaluation index	Age, yaer	Follow up time	Intervention measures
Yves Lacasse	2020	A:123;B:120	Randomized, double blind, placebo-controlled	COPD Simple NOD	Spain Canada	Death or progression to LTOT and pulmonary hemodynamics	A:69 ± 8; B:69 ± 9	3–4 year	room air, 2L/min-4L/min
Fletcher EC	1992	A:19;B:19	Double blind、placebo-controlled、 Randomized	COPD Simple NOD	U.S.A	Death or progression to LTOT and pulmonary hemodynamics	63 ± 6	3 year	Nocturnal oxygen or room air, 3L/min
Chaouat A	1999	A:41;B:35	Double blind、placebo-controlled、Randomized、Open Label	COPD Simple NOD	France	Death or progression to LTOT、pulmonary hemodynamic indexes	A:63 ± 8; B:64 ± 6	35.1 month	Nocturnal oxygen therapy for 8–10 hours a night
Donghui Xu	2015	A:60;B:66	Randomized controlled	COPD Simple NOD	China	Pulmonary function, arterial blood gas index, sleep structure	A:52–82; B:49–82	2 year	Not detailed
Hong Li	2014	A:69;B:69	Randomized controlled	COPD Simple NOD	China	Pulmonary function, arterial blood gas index, times of acute attack, times of hospitalization	A:56.3 ± 4.1; B:50.1 ± 6.7	3 year	Bilateral nasal catheter oxygen inhalation (2-4L/min), daily oxygen inhalation time ༞ 15h
A. Oxygen therapy group; B. Non oxygen therapy group; NOD, nocturnal hypoxemia; COPD, Chronic Obstructive Pulmonary Disease

Table 2

All prognostic/outcome indicators included in the study
Author	Year	LTOT mortality	Death	Progress to LTOT	PaO2/mmHg	PaCO2/mmHg	SaO2/%
Yves Lacasse	2020	A:48/123;B:50/120	A:21/123;B:23/120	A:33/123;B:34/120	/	/	/
Fletcher EC	1992	A:11/19;B:7/19	A:5/19;B:6/19	A:6/19;B:1/19	/	/	/
Chaouat A	1999	A:19/41;B:14/35	A:9/41;B:9/35	A:12/41;B:10/35	/	/	/
Donghui Xu	2015	/	/	/	A:75.16 ± 5.98;B:56.59 ± 6.12	A:50.14 ± 4.29;B:68.51 ± 6.01	/
Hong Li	2014	/	/	/	A:68.27 ± 6.42;B:59.89 ± 6.12	A:45.08 ± 5.74;B:46.8 ± 5.37	A:92.88 ± 2.66;B:88.98 ± 2.96
A, Oxygen therapy group;B, Non oxygen therapy group༛LTOT, long-term oxygen therapy

3.3. Evaluation of oxygen therapy and different outcome indicators

3.3.1 Total case fatality rate of LTOT

There were 3 studies on the combined outcome of COPD oxygen therapy and LTOT [6, 9, 12]. There were 357 patients, including 183 patients in the oxygen therapy group and 174 patients in the control group. There was no statistical heterogeneity between the studies (P = 0.38, I² = 0%), so the fixed effect model was used for analysis. Meta analysis results showed that there was no statistical difference in the total mortality of LTOT between the oxygen therapy group and the non-oxygen therapy group in COPD patients with simple NOD (RR = 1.04; 95% CI: 0.82–1.34, P = 0.73) (Fig. 3).

3.3.2 Mortality

There are 2 studies related to oxygen therapy and mortality in COPD [6, 13]. There were 219 patients, including 164 in the oxygen therapy group and 155 in the control group. There was no statistical heterogeneity between the studies (P = 0.99, I² = 0%), so the fixed effect model was used for analysis. Meta analysis results showed that there was no statistical difference between the oxygen therapy group and the non-oxygen therapy group in the death risk of COPD patients with simple NOD (RR = 0.85; 95% CI: 0.62–1.16, P = 0.31) (Fig. 4).

3.3.3 Progress to LTOT

There are 3 relevant studies on oxygen therapy and progress to LTOT [6, 9, 12]. There were 357 patients, including 183 patients in the oxygen therapy group and 174 patients in the control group. There was no statistical heterogeneity between the studies (P = 0.20, I² = 37%), so the fixed effect model was used for analysis. Meta analysis results showed that there was no statistical difference between the oxygen therapy group and the non-oxygen therapy group in the risk of LTOT events in COPD patients with simple NOD (RR = 1.07; 95% CI: 0.76–1.51, P = 0.68) (Fig. 5).

3.3.4 PaO2

There are 3 relevant studies on oxygen therapy and PaO2 [14, 15]. There were 264 patients, including 129 in the oxygen therapy group and 135 in the control group. There was statistical heterogeneity between the studies (P < 0.00001, I² = 98%), so the random effect model was used to analyze the heterogeneity. The possible sources of heterogeneity were: the average age and age distribution of the subjects were different, the severity of the disease was inconsistent, and the statistical methods were different. Meta analysis results showed that PaO2 in patients with COPD simple NOD in the oxygen therapy group was significantly higher than that in the non-oxygen therapy group (mean difference, MD) = 13.47; 95% CI: 3.49–23.46, P = 0.0008) (Fig. 6).

3.3.5 PaCO2

There are 3 relevant studies on oxygen therapy and PaCO2 [14, 15]. There were 264 patients, including 129 in the oxygen therapy group and 135 in the control group. There is statistical heterogeneity between the studies (P ༜ 0.00001, I² = 99%), so the random effect model is used to analyze. The possible sources of heterogeneity are: the average age and age distribution of the subjects are different, the severity of the disease is inconsistent, and the statistical methods are different. Meta analysis results showed that there was no statistical difference between the oxygen therapy group and the non-oxygen therapy group in PaCO2 of COPD patients with simple NOD (MD = -10.05; 95% CI: − 26.36–6.27, P = 0.23) (Fig. 7).

3.3.6 Publication bias analysis

The funnel diagram of the prognosis study of oxygen therapy and COPD hypoxemia is shown in Fig. 8. The funnel chart is symmetrical at the top and bottom, indicating that there is no publication bias in the included studies.

In this meta-analysis, we systematically reviewed the studies on oxygen therapy and prognosis of COPD patients with simple nocturnal hypoxemia, and finally analyzed five prospective studies. The results showed that oxygen therapy could improve the prognosis of COPD patients with simple nocturnal hypoxemia, but it could not improve the survival rate of patients, control the disease progression to LTOT, and reduce the partial pressure of carbon dioxide.

This study confirmed the results of the study on the prognosis of patients with oxygen therapy and COPD with pure nocturnal hypoxemia. There was no significant difference in the total mortality, LTOT mortality, and LTOT prognosis between the oxygen therapy group and the non-oxygen therapy group. Similar to the results of this study, the meta-analysis of Cranston [16] found that continuous oxygen therapy (at least 15 hours a day) did not seem to improve the survival rate of patients with COPD with simple NOD. The difference is that Cranston [16] did not analyze the mortality and prognosis of LTOT. In Yves Lacasse's [13] study, the end point was total mortality, LTOT mortality, and progression to LTOT. The results showed that the above outcomes could not be improved by oxygen therapy. Yves Lacasse's [13] research comes from multiple centers, with a more complete research scheme and a relatively large sample size, so the level of evidence is also high, which is similar to the results of the above outcome indicators in the meta-analysis results of this study.

This study found that oxygen therapy can improve the PaO2 prognosis of patients with COPD with simple NOD, but there was no significant difference between the two groups at the end of follow-up. Xu et al [15] showed that the number of acute attacks, pulmonary function and arterial blood gas of patients in the oxygen therapy group were significantly improved compared with those in the non-oxygen therapy group. Li et al [14] found that oxygen therapy can improve PaO2, SaO2 and sleep disorders of COPD patients with simple NOD, and delay the progress of lung function through 3-year follow-up. According to Zhang et al [17], pressure support ventilation with biphasic positive pressure mask has obvious effect on improving sleep and respiratory disorder at night and correcting hypoxemia in patients with COPD. However, because the study population is an acute attack population, and the patients were not followed up, they were not included in this meta-analysis. According to the research of Wang et al [7], nocturnal oxygen therapy can correct nocturnal hypoxemia in most COPD patients, and noninvasive continuous positive pressure ventilation can achieve good results in patients with poor efficacy. However, the research population is also acute attack population, and no follow-up was conducted for patients, so it was not included in this meta-analysis.

Heterogeneity analysis: In Xu et al [15] study, there are only upper and lower limits for the age of the subjects, and there is no average age or median age, so it is impossible to judge the age group and distribution of the subjects. In the study of Li et al [14], the age of the subjects was mean ± standard deviation. Xu et al [15] listed the partial pressure of oxygen and carbon dioxide of the subjects before treatment, while Li et al [14] did not mention the level of partial pressure of oxygen and carbon dioxide of the subjects before treatment. The above selection bias or statistical analysis difference may cause the statistical heterogeneity included in the study. Furthermore, the time and duration of oxygen therapy, the selection of oxygen therapy methods, the measures for evaluating the efficacy, and the oxygen therapy methods selected under different conditions are also different. The subjects came from different regions and the duration of follow-up was different.

Limitations of this study: In each study, the average age, age distribution, degree of nocturnal hypoxemia, follow-up time, complications, detection methods, etc. of the subjects are different, which may lead to heterogeneity between different studies. The original studies included may have potential confounding factors. Although some studies use multivariate analysis to reduce confounding bias, the limitations and deficiencies of observational studies cannot avoid confounding bias.

In conclusion, oxygen therapy can improve the prognosis of COPD patients with simple NOD, but oxygen therapy has no significant effect on the survival rate of patients, control the disease progression to LTOT, and reduce the partial pressure of carbon dioxide. Therefore, a larger sample of randomized controlled study is needed to conduct stratified analysis on patients with COPD with simple NOD, and to screen potential populations that may benefit from oxygen therapy.

COPD: chronic obstructive pulmonary disease; NOD: nocturnal hypoxemia; LTOT: long-term oxygen therapy; HR: provided hazard ratio; CI: confidence interval; RR: Relative risk; MD: mean difference.

Author contributions

LS is the guarantor of the content of the manuscript, including the data and analysis. LS , YFC，QXX and GHF had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. LS, YFC, QXX, XZR, XRL, and GHF contributed to the study design, data analysis and interpretation, and the writing.

Funding

This study was not funded.

Availability of data and materials

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Declarations Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Respiratory and Critical Care Medicine, Fuyang Tumor Hospital, Fuyang, No. 146, Hebin East Road, Yingzhou District, Fuyang, China.

2. Faculty of Forensic Medicine, Zhongshan School of Medicine, Sun Yat-sen University, No. 74, Zhongshan Second Road, Yuexiu District, Guangzhou, Guangdong, China.

3. The First Affiliated Hospital of Anhui Medical University. Hefei, China.

Contreras-Garza BM, Update on Clinical Aspects of COPD. The New England journal of medicine. 2019; 381(25).
Interpretation of global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2020 report. Journal of Clinical and Pathology. 2015; 35 (02): 248-251.
Al-Faqawi M , Abuowda Y , Elmassry AE , Böttcher B. Management of chronic obstructive pulmonary disease exacerbations at the Nasser Medical Complex: a clinical audit. The Lancet. 2018; 391.
Fletcher EC , Donner CF, Midgren B, Zielinski J, Levi-Valensi P, Braghiroli A, et al. Survival in COPD patients with a daytime PaO2 greater than 60 mm Hg with and without nocturnal oxyhemoglobin desaturation. Chest. 1992; 101(3).
Sibila O, Mortensen EM, Anzueto A, Laserna E, Restrepo MI. Prior cardiovascular disease increases long-term mortality in COPD patients with pneumonia. Eur Respir J. 2014; 43(1):36-42.
Chaouat A, Weitzenblum E, Kessler R, Charpentier C, Enrhart M, Schott R, et al. A randomized trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease patients. Eur Respir J. 1999;14(5):1002-8.
Wang J, Wang M, Wu Y. Effect of oxygen therapy and positive pressure ventilation on nocturnal hypoxemia in patients with chronic obstructive pulmonary disease Chinese Journal of Internal Medicine. 1997 (08): 18-21.
Tan J, Zheng J, Qi J, Wu J. Observation on Efficacy of Precision Oxygen Therapy on Nocturnal Hypoxemia in COPD Patients. Sichuan Medical Journal. 2019. 40 (01): 43-46.
Fletcher EC, Luckett RA, Goodnight-White S, Miller CC, WQian W, Costarangos-Galarza C. A double-blind trial of nocturnal supplemental oxygen for sleep desaturation in patients with chronic obstructive pulmonary disease and a daytime PaO2 above 60 mm Hg. Am Rev Respir Dis. 1992;145(5):1070-6.
JP. T. Higgins and S. Green, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0, 2011. The Cochrane Collaboration, London, UK.
Moher D , Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015; 4(1):1.
Shamseer L , Moher D , Clarke M , Ghersi D , Liberati A , Petticrew M , et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. 2015; 350:g7647.
Yves L, Frédéric S, François C, Marc B, Bruno P, Paula S, et al. Randomized Trial of Nocturnal Oxygen in Chronic Obstructive Pulmonary Disease. N Engl J Med. 2020; 383(12):1129-1138.
Li H, Liu H, He J, Tian T, Tan J, Yan L, et al. Study of oxygen therapy in COPD patients with nocturnal hypoxia. Journal of Clinical Emergency. 2014; 15 (05): 279-281
Xu D. Clinical study on screening of COPD patients on stable stage with nocturnal hypoxemia and oxygen therapy intervention. Journal of Clinical and Pathology. 2015; 35 (02): 248-251.
Cranston JM, Crockett AJ, Moss JR, Alpers JH. Domiciliary oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005; 2005(4): CD001744.
Zhang H, Gu Y. Effect of mask plus pressure support ventilation on nocturnal hypoxemia in patients with chromic obstrustive pulmonary diseases. China Emergency Medicine for Critical Illness. 1998 (02): 99-101.

FigureS1.tif

Download PDF

Version 1

posted

You are reading this latest preprint version

Prognostic value of oxygen inhalation therapy for simple nocturnal hypoxemia in COPD: a meta-analysis

Status:

Version 1

Abstract

Objective

Methods

Results

Conclusion

Figures

1. Introdiction

2. Materials and Methods

2.1 Inclusion Criteria and Exclusion Criteria

2.2 Search Strategy

2.3 Document Quality Evaluation and Data Extraction

2.4 Statistical Analysis

3. Result

3.1 Literature Search Results

3.2. Characteristics of the Included Studies

3.3. Evaluation of oxygen therapy and different outcome indicators

3.3.1 Total case fatality rate of LTOT

3.3.2 Mortality

3.3.3 Progress to LTOT

3.3.4 PaO2

3.3.5 PaCO2

3.3.6 Publication bias analysis

4. Discussion

Abbreviations

Declarations

References

Supplementary Files

Status:

Version 1